Control of Bemisia tabaci by entomopathogenic fungi isolated from arid soils in Argentina

Entomopathogenic Hypocreales were isolated from arid soils in Argentina using Tenebrio molitor as bait and tested for their biological performance at 30°C and 45–65% RH. Conidial germination was tested in three vegetable oils (sunflower, olive and maize) at two concentrations (1% and 10%) to evaluate their compatibility for further liquid formulations. According to radial growth and germination results, we selected four isolates to test their pathogenicity against second instar B. tabaci nymphs with the selected oil formulations at 30°C. CEP381 and CEP401 showed the highest radial growth. Isolates CEP381, CEP401, CEP413 and CEP409 (Metarhizium spp.) had similar germination percentages as compared with water control when germinated on either sunflower, olive or maize oils at 10% v/v. The highest mortality of B. tabaci was observed for the isolates CEP381 in sunflower oil and CEP401 in olive oil. Molecular identification of isolates was performed using ITS4–5 primers. All isolates belong to the Metarhizium core group. Tested isolates could grow and infect B. tabaci nymphs at 30°C in some of the vegetable oils as carriers, providing new possibilities for integrated pest management of Bemisia tabaci.Fil: Aguilera Sammaritano, Juan Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de San Juan. Facultad de Ingeniería. Instituto de Biotecnología; ArgentinaFil: Lopez Lastra, Claudia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Estudios Parasitológicos y de Vectores. Universidad Nacional de La Plata. Facultad de Ciencias Naturales y Museo. Centro de Estudios Parasitológicos y de Vectores; ArgentinaFil: Leclerque, Andreas. Hochschule Geisenheim University; AlemaniaFil: Vazquez, Fabio. Universidad Nacional de San Juan. Facultad de Ingeniería. Instituto de Biotecnología; ArgentinaFil: Toro, Maria Eugenia. Universidad Nacional de San Juan. Facultad de Ingeniería. Instituto de Biotecnología; ArgentinaFil: D´Alessandro, Celeste Paola. Universidade de Sao Paulo; BrasilFil: Cuthbertson, Andrew G.S.. Independent Science Advisor; Reino UnidoFil: Lechner, Bernardo Ernesto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Micología y Botánica. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Micología y Botánica; Argentin

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Migration Monitoring of Blackcurrant Gall Mite (Cecidophyopsis ribis Westw.) from Buds to Leaves on Several Blackcurrant (Ribes nigrum L.) Cultivars

The blackcurrant gall mite (Cecidophyopsis ribis) is the most important pest of blackcurrant crops. Over recent years withdrawal from plant protection programmes of chemical products (endosulfan and amitraz) used for the control of this pest in Poland, has led to an observed increase in population numbers. In 2013, fenpiroxymate (Ortus 05 SC) became registered for control of this pest. It is deemed best that chemical protection should be used during the migration period; when big gall mites emerge from buds in search of new buds. The studies were carried out in a plantation of blackcurrants during 2011-2013. The assessment of migration of the blackcurrant gall mite was carried out on the cultivars ‘Ben Hope’, ‘Ben Alde’r, ‘Ojeby’n and ‘Ruben’. Every year, from selected cultivars buds were collected. They were then placed on blackcurrant leaves within Petri dishes. After one, three and five days of placing buds on the leaves, the estimated number of eriophyid mites on the leaves was calculated. The data has shown a very useful method for monitoring blackcurrant gall mite, which can be used in calculating the treatment dates for this pest. Also, the data has shown that differences in the periods of migration of the mite are dependent on the cultivar and time of flowering. Among the cultivars observed the least susceptible to colonization by the blackcurrant gall mite was a Polish cultivar ‘Ruben’, while the most susceptible cultivar was ‘Ben Hope’

The entomopathogenic fungus, Metarhizium anisopliae for the European grapevine moth, Lobesia botrana Den. & Schiff. (Lepidoptera: Tortricidae) and its effect to the phytopathogenic fungus, Botrytis cinerea

Abstract The European grapevine moth, Lobesia botrana Den. & Schiff. (Lepidoptera: Tortricidae) and the gray rot fungus (Botrytis cinerea) are two important factors that cause elevated losses of productivity in vineyards globally. The European grapevine moth is one of the most important pests in vineyards around the world, not only because of its direct damage to crops, but also due to its association with the gray rot fungus; both organisms are highly detrimental to the same crop. Currently, there is no effective, economic, and eco-friendly technique that can be applied for the control of both agents. On the other hand, Metarhizium anisopliae belongs to a diverse group of entomopathogenic fungi of asexual reproduction and global distribution. Several Metarhizium isolates have been discovered causing large epizootics to over 300 insects’ species worldwide. In this study, a simple design was conducted to evaluate the potential of native M. anisopliae isolates as one of biological control agents against L. botrana and as possible growth inhibitors to B. cinerea. Entomopathogenic fungal strains were isolated from arid soils under vine (Vitis vinifera) culture. Results suggest that the three entomopathogenic strains (CEP413, CEP589, and CEP591) were highly efficient in controlling larval and pupal stages of L. botrana, with mortality rates ranging from 81 to 98% (within 4–6 days). Also, growth inhibition over B. cinerea strains resulted in percentages ranged from 47 to 64%. Finally, the compatibility of the entomopathogenic strains, with seven commercial fungicides, was evaluated. The potential of the entomopathogenic fungal strains to act as control agents is discussed

Entomopathogenic fungi: Are polisporic isolates more pathogenic than monosporic strains?

Actualmente existen varias cepas de hongos entomopatógenos utilizadas para la fabricación de bio-insecticidas comerciales. Sin embargo, la selección de éstas sigue algunas pautas como la obtención y evaluación de cepas monospóricas (cultivo en masa de microorganismos que provienen de una sola espora) Las principales razones para el uso de cultivos monospóricos en lugar de cultivos polispóricos son: la virulencia atenuada y los posibles “contaminantes” de la misma especie. En este estudio, diferentes aislamientos polispóricos y sus combinaciones monospóricas se pusieron a prueba para evaluar su eficacia respecto a larvas de Tenebrio molitor (L.) como insecto modelo. Los aislamientos polispóricos de hongos entomopatógenos fueron obtenidos de muestras de suelo de regiones agrícolas áridas. Se seleccionaron cuatro aislamientos polispóricos de Metarhizium sp. (Metschn.) (CEP413, CEP589, CEP590 y CEP591) para los bioensayos. Se realizaron pruebas de patogenicidad para evaluar la mortalidad en tres tratamientos, Polispórico completo (FP), Polispórico parcial (PP) y Monospórico puro (PM). La mortalidad acumulada se midió al día 4 después de la infección. El porcentaje de esporulación se evaluó al día 6 después de la infección. La mayor mortalidad se encontró en el tratamiento PF (94%), la menor mortalidad en el día 4 se encontró en PM-CEP413 (32%). Al día 6 el porcentaje de esporulación fue mayor en FP (94%) y fue diferente del resto de tratamientos. Elucidar diferentes combinaciones polispóricas y monospóricas para aumentar la eficacia de las aplicaciones es crucial para ayudar a expandir el uso de bio-insecticidas basados ​​en hongos entomopatógenos

Development and validation of a novel field test kit for European foulbrood

European foulbrood (EFB) is a serious and widespread disease of honey bee larvae. It is a notifiable disease in the United Kingdom under existing legislation, so colonies must be officially screened for signs of disease. The current study developed a rapid and sensitive test to diagnose EFB in the field. A monoclonal antibody, highly specific for its causative agent, Melissococcus plutonius, was produced, optimised and incorporated into a Lateral Flow Device (LFD). Laboratory trials of LFDs found them to be very effective, detecting M. plutonius in 96–100% (n = 137) of EFB-infected samples with no cross-reactivity with other bee brood pathogens. Field validation data was equally robust: correct diagnoses were obtained on 96% (n = 184) of samples subjected to LFD-testing on site; false positives were rare (~1%). EFB LFDs are now issued to all Appointed Bee Inspectors in England and Wales as the sole diagnostic tool for routine confirmation of M. plutonius infection in the field, allowing much more efficient disease detection and control

Root and shoot jasmonic acid induced plants differently affect the performance of bemisia tabaci and its parasitoid encarsia formosa

Contains fulltext : 123479.pdf (publisher's version ) (Closed access